Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
45.51
-0.25 (-0.54%)
Nov 21, 2024, 3:19 PM EST - Market open
Halozyme Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 947.36 | 829.25 | 660.12 | 443.31 | 267.59 | 195.99 | Upgrade
|
| Revenue Growth (YoY) | 21.35% | 25.62% | 48.91% | 65.67% | 36.53% | 29.06% | Upgrade
|
| Cost of Revenue | 249.6 | 268.72 | 205.91 | 117.09 | 77.6 | 186.35 | Upgrade
|
| Gross Profit | 697.75 | 560.53 | 454.21 | 326.23 | 189.99 | 9.64 | Upgrade
|
| Selling, General & Admin | 149.69 | 149.18 | 121.63 | 50.32 | 45.74 | 77.25 | Upgrade
|
| Operating Expenses | 220.74 | 220.46 | 164.77 | 50.32 | 45.74 | 77.25 | Upgrade
|
| Operating Income | 477.01 | 340.07 | 289.43 | 275.9 | 144.26 | -67.61 | Upgrade
|
| Interest Expense | -18.78 | -18.76 | -16.95 | -7.53 | -20.38 | -11.63 | Upgrade
|
| Interest & Investment Income | 10.84 | 10 | 2.15 | 3.36 | 5.43 | 4.52 | Upgrade
|
| EBT Excluding Unusual Items | 469.08 | 331.31 | 274.64 | 271.74 | 129.3 | -74.72 | Upgrade
|
| Merger & Restructuring Charges | - | - | -21.9 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 11.02 | 6.32 | -1.11 | -2.26 | - | 2.47 | Upgrade
|
| Asset Writedown | - | -2.5 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | 13.2 | -2.71 | -20.96 | - | - | Upgrade
|
| Pretax Income | 480.09 | 348.33 | 248.92 | 248.52 | 129.3 | -72.25 | Upgrade
|
| Income Tax Expense | 87.63 | 66.74 | 46.79 | -154.19 | 0.22 | -0.01 | Upgrade
|
| Net Income | 392.47 | 281.59 | 202.13 | 402.71 | 129.09 | -72.24 | Upgrade
|
| Net Income to Common | 392.47 | 281.59 | 202.13 | 402.71 | 129.09 | -72.24 | Upgrade
|
| Net Income Growth | 54.57% | 39.31% | -49.81% | 211.97% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 127 | 132 | 137 | 141 | 136 | 144 | Upgrade
|
| Shares Outstanding (Diluted) | 130 | 134 | 141 | 147 | 141 | 144 | Upgrade
|
| Shares Change (YoY) | -4.66% | -4.56% | -4.22% | 3.77% | -1.99% | 0.51% | Upgrade
|
| EPS (Basic) | 3.08 | 2.13 | 1.48 | 2.86 | 0.95 | -0.50 | Upgrade
|
| EPS (Diluted) | 3.02 | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 | Upgrade
|
| EPS Growth | 61.71% | 45.83% | -47.45% | 201.10% | - | - | Upgrade
|
| Free Cash Flow | 392.71 | 373.28 | 235.3 | 297.98 | 52.95 | -89.46 | Upgrade
|
| Free Cash Flow Per Share | 3.02 | 2.78 | 1.67 | 2.03 | 0.37 | -0.62 | Upgrade
|
| Gross Margin | 73.65% | 67.59% | 68.81% | 73.59% | 71.00% | 4.92% | Upgrade
|
| Operating Margin | 50.35% | 41.01% | 43.85% | 62.24% | 53.91% | -34.50% | Upgrade
|
| Profit Margin | 41.43% | 33.96% | 30.62% | 90.84% | 48.24% | -36.86% | Upgrade
|
| Free Cash Flow Margin | 41.45% | 45.01% | 35.65% | 67.22% | 19.79% | -45.65% | Upgrade
|
| EBITDA | 553 | 416.93 | 336.07 | 277.3 | 145.84 | -65.34 | Upgrade
|
| EBITDA Margin | 58.37% | 50.28% | 50.91% | 62.55% | 54.50% | -33.34% | Upgrade
|
| D&A For EBITDA | 75.99 | 76.86 | 46.64 | 1.4 | 1.58 | 2.27 | Upgrade
|
| EBIT | 477.01 | 340.07 | 289.43 | 275.9 | 144.26 | -67.61 | Upgrade
|
| EBIT Margin | 50.35% | 41.01% | 43.85% | 62.24% | 53.91% | -34.50% | Upgrade
|
| Effective Tax Rate | 18.25% | 19.16% | 18.80% | - | 0.17% | - | Upgrade
|
| Revenue as Reported | 947.36 | 829.25 | 660.12 | 443.31 | 267.59 | 195.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.